We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
-23.88%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
-$47.6M
Cap. Flow
+$663K
Cap. Flow %
0.65%
Top 10 Hldgs %
57.94%
Holding
38
New
9
Increased
8
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
RGNX icon
Regenxbio
RGNX
+$4.79M
2
TECX
Tectonic Therapeutic
TECX
+$4.43M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$4.1M
4
CYTK icon
Cytokinetics
CYTK
+$4.06M
5
AIMT
Aimmune Therapeutics
AIMT
+$2.88M

Top Sells

Rank Stock Value
1
ARQL
Arqule Inc
ARQL
+$11.9M
2
ASND icon
Ascendis Pharma A/S
ASND
+$6.09M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$3.72M
4
USPH icon
US Physical Therapy
USPH
+$2.46M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.29M

Sector Composition

Rank Sector Weight
1 Healthcare 97.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$711M
$1.17M 1.15%
+115,899
New +$1.36M
INSM icon
27
Insmed
INSM
$28.6B
$1.01M 0.99%
+65,400
New +$1.55M
WVE icon
28
Wave Life Sciences
WVE
$1.2B
$556K 0.55%
56,699
-49,287
-47% -$420K
KDNY
29
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$363K 0.36%
27,180
– –
VIRX
30
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$280K 0.28%
19,502
+3,838
+25% +$83.3K
AUTL
31
Autolus Therapeutics
AUTL
$562M
$84K 0.08%
15,006
+1,893
+14% +$17.5K
ASND icon
32
Ascendis Pharma A/S
ASND
$16.8B
– –
-43,775
Closed -$6.09M
SLDB icon
33
Solid Biosciences
SLDB
$826M
– –
-5,366
Closed -$358K
USPH icon
34
US Physical Therapy
USPH
$1.22B
– –
-21,500
Closed -$2.46M
DCPH
35
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-59,818
Closed -$3.72M
ABMD
36
DELISTED
Abiomed Inc
ABMD
– –
-10,138
Closed -$1.73M
DRNA
37
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-104,047
Closed -$2.29M
ARQL
38
DELISTED
Arqule Inc
ARQL
– –
-595,018
Closed -$11.9M
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Burrage Capital Management held 38 positions worth $102M, down 32% from $149M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Burrage Capital Management's Q1 2020 filing shows 9 new, 8 increased, 13 reduced and 7 closed positions. Its largest new stake was Regenxbio: 115,000 shares worth $3.54M. The largest sale was Arqule Inc, an estimated $11.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier.

  • Burrage Capital Management's largest Q1 2020 buy was Regenxbio: 115,000 shares worth $3.54M.
  • Burrage Capital Management added most to Korro Bio in Q1 2020, an estimated $2.6M increase.
  • Burrage Capital Management's biggest Q1 2020 reduction was Aerie Pharmaceuticals, cutting an estimated $1.89M.
  • Burrage Capital Management fully exited Arqule Inc in Q1 2020, selling an estimated $11.9M.
  • Burrage Capital Management's ten largest holdings make up 58% of its $102M portfolio in Q1 2020.
  • Burrage Capital Management opened 9 new positions and closed 7 in Q1 2020.
  • Burrage Capital Management's portfolio value fell 32% quarter-over-quarter to $102M.

Based on Burrage Capital Management's 13F filing for Q1 2020, filed 14 May 2020.